Does nutrition have a role in peripheral vascular disease?

British Journal of Nutrition

Volumn 95, Issue 2, 2006, Pages 217-229

  Carrero, Juan J ^a   Grimble, Robert F ^b  

^a UNIVERSITY OF GRANADA   (Spain)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

Fish oil; Olive oil; Peripheral vascular disease; Vitamin C; Vitamin E

Indexed keywords

5,8,11,14,17 ICOSAPENTAENOIC ACID; ACETYLSALICYLIC ACID; ALLICIN; ALPHA TOCOPHEROL; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; ARGININE; ASCORBIC ACID; BETA CAROTENE; CARNITINE; CERVONIC ACID; CYANOCOBALAMIN; FISH OIL; FOLIC ACID; GAMMA LINOLENIC ACID; GARLIC EXTRACT; GINKGO BILOBA EXTRACT; OLIVE OIL; OMEGA 3 FATTY ACID; PHYTOALEXIN; PLACEBO; PROPIONYLCARNITINE; PYRIDOXINE; ANTIOXIDANT; EDIBLE OIL; VEGETABLE OIL; VITAMIN B COMPLEX;

ALCOHOL CONSUMPTION; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ATHEROGENESIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DIET SUPPLEMENTATION; DIETARY FIBER; DISEASE PREDISPOSITION; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; FAT INTAKE; FEEDING BEHAVIOR; HIGH RISK PATIENT; HUMAN; ISCHEMIC HEART DISEASE; LOW DRUG DOSE; META ANALYSIS; MORTALITY; NUTRITION; PERIPHERAL VASCULAR DISEASE; PRIMARY PREVENTION; REVIEW; RISK FACTOR; RISK REDUCTION; SYSTEMATIC REVIEW; VITAMIN INTAKE; VITAMIN SUPPLEMENTATION; ATHEROSCLEROSIS; METABOLISM; PATHOPHYSIOLOGY;

ALLIUM SATIVUM; GINKGO BILOBA;

ANTIOXIDANTS; ASCORBIC ACID; ATHEROSCLEROSIS; CARNITINE; DIETARY FATS, UNSATURATED; DIETARY FIBER; FISH OILS; HUMANS; NUTRITION PHYSIOLOGY; PERIPHERAL VASCULAR DISEASES; PLANT OILS; VITAMIN B COMPLEX; VITAMIN E;

EID: 33644903786     PISSN: 00071145     EISSN: 14752662     Source Type: Journal    
DOI: 10.1079/BJN20051616     Document Type: Review

References (165)

1. Alarcon de la Lastra C, Barranco MD, Motilva V & Herrerias JM (2001) Mediterranean diet and health: biological importance of olive oil. Curr Pharm Des 7, 933-950.
2. Anonymous (1998) Lowering blood homocysteine with folic acid based supplements: meta-analysis of randomised trials. Homocysteine Lowering Trialists' Collaboration. BMJ 316, 894-898.
3. Anonymous (2000) Management of peripheral arterial disease (PAD). TransAtlantic Inter-Society Consensus (TASC). Eur J Vasc Endovasc Surg 19, S1-S250.
4. Bakker SJ, Ijzerman RG, Teerlink T, Westerhoff HV, Gans RO & Heine RJ (2000) Cytosolic triglycerides and oxidative stress in central obesity: the missing link between excessive atherosclerosis, endothelial dysfunction, and beta-cell failure?" Atherosclerosis 148, 17-21.
5. Barker GA, Green S, Askew CD, Green AA & Walker PJ (2001) Effect of propionyl-L-carnitine on exercise performance in peripheral arterial disease. Med Sci Sports Exerc 33, 1415-1422.
6. Bauer U (1984) Six-month double-blind randomised clinical trial of Ginkgo biloba extract versus placebo in two parallel groups in patients suffering from peripheral arterial insufficiency. Arzneimittelforsschung 34, 716-720.
7. Bazzano LA, He J, Ogden LG, Loria CM & Whelton PK (2003) Dietary fiber intake and reduced risk of coronary heart disease in US men and women: the National Health and Nutrition Examination Survey I Epidemiologic Follow-up Study. Arch Intern Med 163, 1897-1904.
8. Blann AD, Amiral J, McCollum CN & Lip GY (2000a) Differences in free and total tissue factor pathway inhibitor, and tissue factor in peripheral artery disease compared to healthy controls. Atherosclerosis 152, 29-34.
9. Blann AD, Farrell A, Picton A & McCollum CN (2000b) Relationship between endothelial cell markers and arterial stenosis in peripheral and carotid artery disease. Thromb Res 97, 209-216.
10. Blann AD, Seigneur M, Steiner M, Boisseau MR & McCollum CN (1997) Circulating endothelial cell markers in peripheral vascular disease: relationship to the location and extent of atherosclerotic disease. Eur J Clin Invest 27, 916-921.
11. Blume J, Kieser M & Hölscher U (1996) Placebo-controlled, double-blind study on the efficacy of Ginkgo biloba special extract EGb 761 in maximum-level trained patients with intermittent claudication. Vasa 25, 265-274.
12. Blume J, Kieser M & Hölscher U (1998) Efficacy of Ginkgo biloba special extract EGb 761 in peripheral occlusive disease. Fortschr Med 116, 137-143.
13. Boers GH (1997) Hyperhomocysteinemia as a risk factor for arterial and venous disease. A review of evidence and relevance. Thromb Haemost 78, 520-522.
14. Boger RH, Bode-Boger SM, Thiele W, Creutzig A, Alexander K & Frolich JC (1998) Restoring vascular nitric oxide formation by L-arginine improves the symptoms of intermittent claudication in patients with peripheral arterial occlusive disease. J Am Coll Cardiol 32, 1336-1344.
15. Boyd AM & Marks J (1963) Treatment of intermittent claudication. A reappraisal of alpha-tocopherol. Angiology 14, 198-208.
16. Brevetti G, Chiariello M, Ferulano G, Policicchio A, Nevola E, Rossini A, Ambrosio G, Siliprandi N & Angelini C (1998a) Increases in walking distance in patients with peripheral vascular disease treated with L-carnitine: a double-blind, cross-over study. Circulation 77, 767-773.
17. Brevetti G, Diehm C & Lambert D (1999) European multicenter study on propionyl-L-carnitine in intermittent claudication. J Am Coll Cardiol 34, 1618-1624.
18. Brevetti G, Martone VD, Perna S, Cacciatore F, Corrado S, Di Donato A & Di Iorio A (1998b) Intermittent claudication and risk of cardiovascular events. Angiology 49, 843-848.
19. Brevetti G, Perna S, Sabba C, Martone VD, Di Iorio A & Barletta G (1997) Effect of propionyl-L-carnitine on quality of life in intermittent claudication. Am J Cardiol 79, 777-780.
20. Brevetti G, Silvestro A, Di Giacomo S, Bucar R, Di Donato A, Schiano V & Scopacasa F (2003) Endothelial dysfunction in peripheral arterial disease is related to increased plasma markers of inflammation and severity of peripheral circulatory impairment, but not to classic risk factors and atherosclerotic burden. J Vasc Surg 38, 374-379.
21. Bronstrup A, Hages M, Prinz-Langenohl R & Pietrzik K (1998) Effects of folic acid and combinations of folic acid and vitamin B-12 on plasma homocysteine concentrations in healthy, young women. Am J Clin Nutr 68, 1104-1110.
22. Calder PC (2004) n-3 Fatty acids and cardiovascular disease: evidence explained and mechanisms explored. Clin Sci (Lond) 107, 1-11.
23. Camargo CA Jr, Stampfer MJ, Glynn RJ, Gaziano JM, Manson JE, Goldhaber SZ & Hennekens CH (1997) Prospective study of moderate alcohol consumption and risk of peripheral arterial disease in US male physicians. Circulation 95, 577-580.
24. Carrero JJ, Fonolla J, González-Santiago M, Baro L, Jimenez J, Boza J & Lopez-Huertas E (2004a) Health effects due to folic acid supplementation. Food fortification strategies to achieve adequate folate status. Nutrafoods 3, 5-13.
25. Carrero JJ, Lopez-Huertas E, Salmeron LM, Baro L & Ros E (2005a) Daily supplementation with (n-3) PUFAs, oleic acid, folic acid, and vitamins B-6 and E increases pain-free walking distance and improves risk factors in men with peripheral vascular disease. J Nutr 135, 1393-1399.
26. Carrero JJ, Madden J, Hadley J, et al. (2004b) Fish oil alters the balance between LPS stimulated leukotriene B4 and prostaglandin E2 production by PBMCs in patients with peripheral vascular disease but not in healthy controls. Clin Nutr 23, 789-790.
27. Carrero JJ, Martin-Bautista E, Baro L, Fonolla J, Jimenez J, Boza JJ & López-Huertas E (2005b) Cardiovascular effects of omega-3 fatty acids and alternatives to increase intake. Nutr Hosp 20, 56-62.
28. Cassar K, Coull R, Bachoo P, Macaulay E & Brittenden J (2003) Management of secondary risk factors in patients with intermittent claudication. Eur J Vasc Endovasc Surg 26, 262-266.
29. Cheng SW, Ting AC & Wong J (1997) Fasting total plasma homocysteine and atherosclerotic peripheral vascular disease. Ann Vasc Surg 11, 217-223.
30. Ciccarone E, Di Castelnuovo A, Assanelli D, Archetti S, Ruggeri G, Salcuni N, Donati MB, Capani F, Laciovalli L & GENDIABE Investigators (2003) Homocysteine levels are associated with the severity of peripheral arterial disease in type 2 diabetic patients. J Thromb Haemost 1, 2540-2547.
31. Cleophas TJ, Hornstra N, van Hoogstraten B & van der Meulen J (2000) Homocysteine, a risk factor for coronary artery disease or not? A meta-analysis. Am J Cardiol 86, 1005-1009.
32. Criqui MH, Langer RD, Fronek A, Feigelson HS, Klauber MR, McCann TJ & Browner D (1992) Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med 326, 381-386.
33. Dal Lago A, De Martini D, Flore R, et al. (1999) Effects of propionyl-L-carnitine on peripheral arterial obliterative disease of the lower limbs: a double-blind clinical trial. Drugs Exp Clin Res 25, 29-36.
34. de Jong SC, Stehouwer CD, van den Berg M, Geurts TW, Bouter LM & Rauwerda JA (1999) Normohomocysteinaemia and vitamin-treated hyperhomocysteinaemia are associated with similar risks of cardiovascular events in patients with premature peripheral arterial occlusive disease. A prospective cohort study. J Intern Med 246, 87-96.
35. de Vriese AS, Blom HJ, Heil SG, Mortier S, Kluijtmans LA, Van de Voorde J & Lameire NH (2004) Endothelium-derived hyperpolarizing factor-mediated renal vasodilatory response is impaired during acute and chronic hyperhomocysteinemia. Circulation 109, 2331-2336.
36. Diehr P & Beresford SA (2003) The relation of dietary patterns to future survival, health, and cardiovascular events in older adults. J Clin Epidemiol 56, 1224-1235.
37. Djousse L, Levy D, Murabito JM, Cupples LA & Ellison RC (2000) Alcohol consumption and risk of intermittent claudication in the Framingham Heart Study. Circulation 102, 3092-3097.
38. Donnan PT, Thomson M, Fowkes FG, Prescott RJ & Housley E (1993) Diet as a risk factor for peripheral arterial disease in the general population: the Edinburgh Artery Study. Am J Clin Nutr 57, 917-921.
39. Drexel H, Steurer J, Muntwyler J, Meienberg S, Schmid HR, Schneider E, Grochenig E & Amann FW (1996) Predictors of the presence and extent of peripheral arterial occlusive disease. Circulation 94, 199-205.
40. Drossos GE, Toumpoulis IK, Katritsis DG, Ioannidis JP, Kontogiorgi P, Svarna E & Anagnostopoulos CE (2003) Is vitamin C superior to diltiazem for radial artery vasodilation in patients awaiting coronary artery bypass grafting?" J Thorac Cardiovasc Surg 125, 330-335.
41. Duthie GC, Wahle KWJ & James PWT (1989) Oxidants, antioxidants and cardiovascular disease. Nutr Res Rev 2, 51-62.
42. Ernst E (1989) Effects of n-3 fatty acids on blood theology. J Intern Med 225, Suppl., 129-132.
43. Farrell PM, Bieri JG, Fratantoni JF, Wood RE & di Sant'Agnese PA (1977) The occurrence and effects of human vitamin E deficiency. A study in patients with cystic fibrosis. J Clin Invest 60, 233-241.
44. Ferrara LA, Raimondi AS, d'Episcopo L, Guida L, Dello Russo A & Marotta T (2000) Olive oil and reduced need for antihypertensive medications. Arch Intern Med 160, 837-842.
45. Ferrari R, Visioli O, Guarnieri C & Caldarera M (1983) Vitamin E and the heart: possible role as antioxidant. Acta Vitaminol Enzymol 5, 11-22.
46. Fowkes FG, Housley E, Riemersma RA, Macintyre CC, Cawood EH, Prescott RJ & Ruckley CV (1992) Smoking, lipids, glucose intolerance, and blood pressure as risk factors for peripheral atherosclerosis compared with ischemic heart disease in the Edinburgh Artery Study. Am J Epidemiol 135, 331-340.
47. Frankel EN, Kanner J, German JB, Parks E & Kinsella JE (1993) Inhibition of oxidation of human low-density lipoprotein by phenolic substances in red wine., Lancet 341, 454-457.
48. Gans RO, Bilo HJ, Weersink EG, Rauwerda JA, Fonk T, Popp-Snijders C & Donker AJ (1990) Fish oil supplementation in patients with stable claudication. Am J Surg 160, 490-495.
49. Gokce N, Keaney JF Jr, Hunter LM, Watkins MT, Nedelijkovic ZS, Menzoian JO & Vita JA (2003) Predictive value of noninvasively determined endothelial dysfunction for long-term cardiovascular events in patients with peripheral vascular disease. J Am Coll Cardiol 41, 1769-1775.
50. Gorinstein S, Zemser M, Berliner M, Goldstein R, Libman I, Trakhtenberg S & Caspi A (1997) Moderate beer consumption and positive biochemical changes in patients with coronary atherosclerosis. J Intern Med 242, 219-224.
51. Graham IM, Daly LE, Refsum HM, et al. (1997) Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. JAMA 277, 1775-1781.
52. Grimble RF, Howell WM, O'Reilly G, Turner SJ, Markovic O, Hirrell S, East JM & Calder PC (2002) The ability of fish oil to suppress tumor necrosis factor-alpha production by peripheral blood mononuclear cells in healthy men is associated with polymorphisms in genes which influence TNF-alpha production. Am J Clin Nutr 76, 454-459.
53. Haeger K (1974) Long-time treatment of intermittent claudication with vitamin E. Am J Clin Nutr 27, 1179-1181.
54. Halperin JL (2002) Evaluation of patients with peripheral vascular disease. Thrombosis Research 106, 303-311.
55. Hamilton M, Wilson GM, Armitage P & Boyd JT (1953) The treatment of intermittent claudication with vitamin E. Lancet i, 367-370.
56. Henke PK, Blackburn S, Proctor MC, Stevens J, Mukherjee D, Rajagopalin S, Upchurch GR Jr, Stanley JC & Eagle KA (2004) Patients undergoing infrainguinal bypass to treat atherosclerotic vascular disease are underprescribed cardioprotective medications: effect on graft patency, limb salvage, and mortality. J Vasc Surg 39, 357-365.
57. Hertzer NR (1991) The natural history of peripheral vascular disease: implications for its management. Circulation 83, 12-19.
58. Hiatt WR (1994) Medical treatment of the patient with intermittent claudication. J Vasc Tech 18, 311-315.
59. Hiatt WR (2001) Medical treatment of peripheral arterial disease and claudication. N Engl J Med 344, 1608-1621.
60. Hiatt WR, Hoag S & Hamman RF (1995) Effect of diagnostic criteria on the prevalence of peripheral arterial disease: the San Luis Valley Diabetes Study. Circulation 91, 1472-1479.
61. Hirsch AT & Hiatt WR; PARTNERS Steering Committee (2001) PAD awareness, risk, and treatment: new resources for survival - the USA PARTNERS program. Vasc Med 6, 9-12.
62. Ho M, Maple C, Bancroft A, McLaren M & Belch JJ (1999) The beneficial effects of omega-3 and omega-6 essential fatty acid supplementation on red blood cell rheology. Prostaglandins Leukot Essent Fatty Acids 61, 13-17.
63. Hooper L, Griffiths E, Abrahams B, et al. (2004) Dietetic guidelines: diet in secondary prevention of cardiovascular disease (first update June 2003). J Hum Nutr Diet 17, 337-349.
64. Hunninghake DB, Miller VT, LaRosa JC, Kinosian B, Brown V, Howard WJ, DiSerio FJ & O'Connor RR (1994) Hypocholesterolemic effects of a dietary fibre supplement. Am J Clin Nutr 59, 1050-1054.
65. James SL, Muir JG, Curtis SL & Gibson PR (2003) Dietary fibre: a roughage guide. Intern Med J 33, 291-296.
66. Jenkins DJ, Axelsen M, Kendall CW, Augustin LS, Vuksan V & Smith U (2000) Dietary fibre, lente carbohydrates and the insulin-resistant diseases. Br J Nutr 83, 157-163.
67. Jenkins DJ & Jenkins AL (1985) Dietary fibre and the glycemic response. Proc Soc Exp Biol Med 180, 422-431.
68. Jepson RG, Fowkes FG, Donnan PT & Housley E (1995) Alcohol intake as a risk factor for peripheral arterial disease in the general population in the Edinburgh Artery Study. Eur J Epidemiol 11, 9-14.
69. Jepson RG, Kleijnen J & Leng GC (2005) Garlic for peripheral arterial occlusive disease (Cochrane Review). In The Cochrane Library, issue 3. Chichester, UK: John Wiley & Sons, Ltd.
70. Jeukendrup AE (2002) Regulation of fat metabolism in skeletal muscle. Ann N Y Acad Sci 967, 217-235.
71. Kanayasu-Toyoda T, Morita I, Hibino H, Nakao-Hayashi J, Ito H & Murota S (1993) Eicosapentaenoic acid abolishes the proatherogenic effects of cholesterol: effects on migration of bovine smooth muscle and endothelial cells in vitro. Prostaglandins Leukot Essent Fatty Acids 48, 463-468.
72. Kanayasu-Toyoda T, Morita I & Murota S (1996) Docosapentaenoic acid (22: 5, n-3), an elongation metabolite of eicosapentaenoic acid (20: 5, n-3), is a potent stimulator of endothelial cell migration on pretreatment in vitro. Prostaglandins Leukot Essent Fatty Acids 54, 319-325.
73. Karlic H & Lohninger A (2004) Supplementation of L-carnitine in athletes: does it make sense?" Nutrition 20, 709-715.
74. Katsouyanni K, Skalkidis Y, Petridou E, Polychronopoulou-Trichopoulou A, Willett W & Trichopoulos D (1991) Diet and peripheral arterial occlusive disease: the role of poly-, mono-, and saturated fatty acids. Am J Epidemiol 133, 24-31.
75. Kearns SR, Daly AF, Sheehan K, Murray P, Kelly C & Bouchier-Hayes D (2004) Oral vitamin C reduces the injury to skeletal muscle caused by compartment syndrome. J Bone Joint Surg Br 86, 906-911.
76. Khaira HS, Maxwell SR & Shearman CP (1995) Antioxidant consumption during exercise in intermittent claudication. Br J Surg 82, 1660-1662.
77. Khaira HS, Maxwell SR, Thomason H, Thorpe GH, Green MA & Shearman CP (1996) Antioxidant depletion during aortic aneurysm repair. Br J Surg 83, 401-403.
78. Kiesewetter H, Jung F, Jung EM, Blume J, Mrowietz C, Birk A, Koscielny J & Wenzel E (1993) Effects of garlic coated tablets in peripheral arterial occlusive disease. Clin Investig 71, 383-386.
79. King DE, Egan BM & Geesey ME (2003) Relation of dietary fat and fiber to elevation of C-reactive protein. Am J Cardiol 92, 1335-1339.
80. Kinlay S, Behrendt D, Fang JC, Delegrange D, Morrow J, Witztum JL, Rifai N, Selwyn NP, Creager MA & Ganz P (2004) Long-term effect of combined vitamins E and C on coronary and peripheral endothelial function. J Am Coll Cardiol 43, 629-634.
81. Kleijnen J & Knipschild P (1992) Ginkgo biloba. Lancet 340, 1136-1139.
82. Kleijnen J & Mackerras D (2004) Vitamin E for intermittent claudication (Cochrane Review). In The Cochrane Library, issue 3. Chichester, UK: John Wiley & Sons, Ltd.
83. Klipstein-Grobusch K, den Breeijen JH, Grobbee DE, Boeing H, Hofman A & Witteman JC (2001) Dietary antioxidants and peripheral arterial disease: the Rotterdam Study. Am J Epidemiol 154, 145-149.
84. Koga T, Claycombe K & Meydani M (2002) Homocysteine increases monocyte and T-cell adhesion to human aortic endothelial cells. Atherosclerosis 161, 365-374.
85. Kuan YM, E Dear A & Grigg MJ (2002) Homocysteine: an aetiological contributor to peripheral vascular arterial disease. ANZ J Surg 72, 668-671.
86. Langlois M, Duprez D, Delanghe J, De Buyzere M & Clement DL (2001) Serum vitamin C concentration is low in peripheral arterial disease and is associated with inflammation and severity of atherosclerosis. Circulation 103, 1863-1868.
87. Leng GC & Fowkes FGR (1993) The epidemiology of peripheral arterial disease. Vasc Med Rev 4, 5-18.
88. Leng GC, Fowkes FG, Lee AJ, Dunbar J, Housley E & Ruckley CV (1996) Use of ankle brachial pressure index to predict cardiovascular events and death: a cohort study. BMJ 313, 1440-1444.
89. Leng GC, Lee AJ, Fowkes FG, Jepson RG, Lowe GD, Skinner ER & Mowat BF (1998) Randomized controlled trial of gamma-linolenic acid and eicosapentaenoic acid in peripheral arterial disease. Clin Nutr 17, 265-271.
90. Lentz SR & Sadler JE (1991) Inhibition of thrombomodulin surface expression and protein C activation by the thrombogenic agent homocysteine. J Clin Invest 88, 1906-1914.
91. Liese AD, Roach AK, Sparks KC, Marquart L, D'Agostino RB Jr & Mayer-Davis EJ (2003) Whole-grain intake and insulin sensitivity: the Insulin Resistance Atherosclerosis Study. Am J Clin Nutr 78, 965-971.
92. Livingstone PD & Jones C (1958) Treatment of intermittent claudication with vitamin E. Lancet ii, 602-664.
93. Lowe GD, Fowkes FG, Dawes J, Donnan PT, Lennie SE & Housley E (1993) Blood viscosity, fibrinogen, and activation of coagulation and leukocytes in peripheral arterial disease and the normal population in the Edinburgh Artery Study. Circulation 87, 1915-1920.
94. McDermott MM, Mehta S, Ahn H & Greenland P (1997) Atherosclerotic risk factors are less intensively treated in patients with peripheral arterial disease than in patients with coronary artery disease. J Gen Intern Med 12, 209-215.
95. Marckmann P, Sandstrom B & Jespersen J (1993) Dietary effects on circadian fluctuation in human blood coagulation factor VII and fibrinolysis. Atherosclerosis 101, 225-234.
96. Markovic O, O'Reilly G, Fussell HM, Turner SJ, Calder PC, Howell WM & Grimble RF (2004) Role of single nucleotide polymorphisms of proinflammatory cytokine genes on the relationship between serum lipids and inflammatory parameters, and the lipid-lowering effect of fish oil in healthy males. Clin Nutr 23, 1084-1095.
97. Maxwell AJ, Anderson BE & Cooke JP (2000) Nutritional therapy for peripheral arterial disease: a double-blind, placebo-controlled, randomized trial of HeartBar. Vasc Med 5, 11-19.
98. Mennen LI, Balkau B, Vol S, Caces E & Eschwege E (1999) Fibrinogen: a possible link between alcohol consumption and cardiovascular disease? DESIR Study Group. Arterioscler Thromb Vasc Biol 19, 887-892.
99. Merchant AT, Hu FB, Spiegelman D, Willett WC, Rimm EB & Ascherio A (2003a) The use of B vitamin supplements and peripheral arterial disease risk in men are inversely related. J Nutr 133, 2863-2867.
100. Merchant AT, Hu FB, Spiegelman D, Willett WC, Rimm EB & Ascherio A (2003b) Dietary fibre reduces peripheral arterial disease risk in men. J Nutr 133, 3658-3663.
101. Meydani M, Natiello F, Goldin B, Free N, Woods M, Schaefer E, Blumberg JB & Gorbach SL (1991) Effect of long-term fish oil supplementation on vitamin E status and lipid peroxidation in women. J Nutr 121, 484-491.
102. Mori TA, Vandongen R, Mahanian F & Douglas A (1992) Plasma lipid levels and platelet and neutrophil function in patients with vascular disease following fish oil and olive oil supplementation. Metabolism 41, 1059-1067.
103. Morrissey PA & Sheehy PJ (1999) Optimal nutrition: vitamin E. Proc Nutr Soc 58, 459-468.
104. Mujumdar VS, Aru GM & Tyagi SC (2001) Induction of oxidative stress by homocyst(e)ine impairs endothelial function. J Cell Biochem 82, 491-500.
105. Mukherjee D, Lingam P, Chetcuti S, Grossman PM, Moscucci M, Luciano AE & Eagle KA (2002) Missed opportunities to treat atherosclerosis in patients undergoing peripheral vascular interventions: insights from the University of Michigan Peripheral Vascular Disease Quality Improvement Initiative, (PVD-Q12). Circulation 106, 1909-1912.
106. Muluk SC, Muluk VS, Kelley ME, Whittle JC, Tierney JA, Webster MW & Makaroun MS (2001) Outcome events in patients with claudication: a 15-years study in 2777 patients. J Vasc Surg 33, 251-257.
107. Nappo F, De Rosa N, Marfella R, De Lucia D, Ingrosso D, Perna AF, Farzati B & Giugliano D (1999) Impairment of endothelial functions by acute hyperhomocysteinemia and reversal by antioxidant vitamins. JAMA 281, 2113-2118.
108. National Cholesterol Education Programme (2002) Third Report of the Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III), National Institutes of Health publication number 02-5215. Washington, DC: NIH.
109. Pereira MA, O'Reilly E, Augustsson K, et al. (2004) Dietary fiber and risk of coronary heart disease: a pooled analysis of cohort studies. Arch Intern Med 164, 370-376.
110. Peters H, Kieser M & Hölscher U (1998) Demonstration of the efficacy of Ginkgo biloba special extract EGb 761® on intermittent claudication: a placebo-controlled, double-blind multicenter trial. VASA 27, 106-110.
111. Philipp CS, Cisar LA, Kim HC, Wilson AC, Saidi P & Kostis JB (1997) Association of hemostatic factors with peripheral vascular disease. Am Heart J 134, 978-984.
112. Piesse JW (1984) Vitamin E and peripheral vascular disease. Int Clin Nutr Rev 4, 178-182.
113. Pittler MH & Ernst E (2000) Ginkgo biloba extract for the treatment of intermittent claudication: a meta-analysis of randomized trials. Am J Med 108, 276-281.
114. Podmore ID, Griffiths HR, Herbert KE, Mistry N, Mistry P & Lunec J (1998) Vitamin C exhibits pro-oxidant properties. Nature 392, 559.
115. Poredos P, Golob M & Jensterle M (2003) Interrelationship between peripheral arterial occlusive disease, carotid atherosclerosis and flow mediated dilation of the brachial artery. Int Angiol 22, 83-87.
116. Ramirez-Tortosa C, Lopez-Pedrosa JM, Suarez A, Ros E, Mataix J & Gil A (1999a) Olive oil- and fish oil-enriched diets modify plasma lipids and susceptibility of LDL to oxidative modification in free-living male patients with peripheral vascular disease: the Spanish Nutrition Study. Br J Nutr 82, 31-39.
117. Ramirez-Tortosa MC, Urbano G, Lopez-Jurado M, Nestares T, Gomez MC, Mir A, Ros E, Mataix J & Gil A (1999b) Extra-virgin olive oil increases the resistance of LDL to oxidation more than refined olive oil in free-living men with peripheral vascular disease. J Nutr 129, 2177-2183.
118. Refsum H, Ueland PM, Nygard O & Vollset SE (1998) Homocysteine and cardiovascular disease. Annu Rev Med 49, 31-62.
119. Reichl D & Miller NE (1989) Pathophysiology of reverse cholesterol transport. Insights from inherited disorders of lipoprotein metabolism. Arteriosclerosis 9, 785-797.
120. Renaud SC & Ruf JC (1996) Effects of alcohol on platelet functions. Clin Chim Acta 246, 77-89.
121. Riba R, Nicolaou A, Troxler M, Homer-Vaniasinkam S & Naseem KM (2004) Altered platelet reactivity in peripheral vascular disease complicated with elevated plasma homocysteine levels. Atherosclerosis 175, 69-75.
122. Ridker PM, Vaughan DE, Stampfer MJ, Glynn RJ & Hennekens CH (1994) Association of moderate alcohol consumption and plasma concentration of endogenous tissue-type plasminogen activator. JAMA 272, 929-933.
123. Rodgers GM & Kane WH (1986) Activation of endogenous factor V by homocysteine-induce vascular endothelial cell activator. J Clin Invest 11, 1909-1916.
124. Ross R (1999) Related atherosclerosis - an inflammatory disease. N Engl J Med 340, 115-126.
125. Rossi E, Biasucci LM, Citterio F, Pelliccioni S, Monaco C, Ginnetti F, Angiolillo DJ, Grieco G, Liuzzo G & Maseri A (2002) Risk of myocardial infarction and angina in patients with severe peripheral vascular disease: predictive role of C-reactive protein. Circulation 105, 800-803.
126. Ruiz-Gutierrez V, Muriana FJ, Guerrero A, Cert AM & Villar J (1996) Plasma lipids, erythrocyte membrane lipids and blood pressure of hypertensive women after ingestion of dietary oleic acid from two different sources. J Hypertens 14, 1483-1490.
127. Schneider B (1992) Ginkgo biloba extract in peripheral arterial disease. Meta-analysis of controlled clinical trials. Arzneimittelforschung 42, 428-436.
128. Schweizer J & Hautmann C (1999) Comparison of two dosages of Ginkgo biloba extract EGb 761 in patients with peripheral arterial occlusive disease Fontaine's stage IIb. Arzneimittelforschung 49, 900-904.
129. Shute EV, Vogelsang AB, Skelton FR & Shute WE (1948) The influence of vitamin E on vascular disease. Surg Gynaecol Obst 86, 1-8.
130. Signorelli SS, Mazzarino MC, Di Pino L, et al. (2003) High circulating levels of cytokines (IL-6 and TNFalpha), adhesion molecules (VCAM-1 and ICAM-1) and selectins in patients with peripheral arterial disease at rest and after a treadmill test. Vasc Med 8, 15-19.
131. Silverman MD, Tumuluri RJ, Davis M, Lopez G, Rosenbaum JT & Lelkes PI (2002) Homocysteine upregulates vascular cell adhesion molecule-1 expression in cultured human aortic endothelial cells and enhances monocyte adhesion. Arterioscler Thromb Vasc Biol 22, 587-592.
132. Silvestro A, Scopacasa F, Oliva G, de Cristofaro T, Iuliano L & Brevetti G (2002) Vitamin C prevents endothelial dysfunction induced by acute exercise in patients with intermittent claudication. Atherosclerosis 165, 277-283.
133. Simchon S, Jan KM & Chien S (1987) Influence of reduced red cell deformability on regional blood flow. Am J Physiol 253, 898-903.
134. Smit AJ (1992) Medical treatment of peripheral vascular disease: are there new perspectives?" Vasa Supplemental 34, 20-24.
135. Sommerfield T & Hiatt WR (2004) Omega-3 fatty acids for intermittent claudication (Cochrane review). In The Cochrane Library, issue 3, Chichester, UK: John Wiley & Sons, Ltd.
136. Spark JI, Robinson JM, Gallavin L, Gough MJ, Homer-Vanniasinkam S, Kester RC & Scott DJ (2002) Patients with chronic critical limb ischemia have reduced total antioxidant capacity and impaired nutritional status. Eur J Vasc Endovasc Surg 24, 535-539.
137. Stamler JS, Osborne JA, Jaraki O, Rabbani LE, Mullins M, Singel D & Loscalzo J (1993) Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen. J Clin Invest 91, 308-318.
138. Stark AH & Madar Z (2002) Olive oil as a functional food: epidemiology and nutritional approaches. Nutr Rev 60, 170-176.
139. Steinberg D (1991) Antioxidants and atherosclerosis: a current assessment. Circulation 84, 1420-1425.
140. Steiner M & Mower R (1982) Mechanism of action of vitamin E on platelet function. Ann N Y Acad Sci 393, 289-299.
141. Stringer MD, Gorog PG, Freeman A & Kakkar VV (1989) Lipid peroxides and atherosclerosis. BMJ 298, 281-284.
142. Tabet S & Berg AO, for the US Preventive Services Task Force (1996) Screening for peripheral arterial disease. In Guide to Clinical Preventive Services: Report of the US Preventive Services Task Force, pp. 63-66. Baltimore, MD: Williams & Wilkins.
143. Taylor LM Jr, DeFrang RD, Harris EJ Jr & Porter JM (1991) The association of elevated plasma homocyst(e)ine with progression of symptomatic peripheral arterial disease. J Vasc Surg 13, 128-136.
144. Taylor LM Jr, Moneta GL, Sexton GJ, Schuff RA & Porter JM (1999) Prospective blinded study of the relationship between plasma homocysteine and progression of symptomatic peripheral arterial disease. J Vasc Surg 29, 8-21.
145. Thies F, Garry JM, Yaqoob P, Rerkasem K, Williams J, Shearman CP, Gallagher PJ, Calder PC & Grimble RF (2003) Association of n-3 polyunsaturated fatty acids with stability of atherosclerotic plaques: a randomised controlled trial. Lancet 361, 477-485.
146. Thorburn A, Muir J & Proietto J (1993) Carbohydrate fermentation decreases hepatic glucose output in healthy subjects. Metabolism 42, 780-785.
147. Tornwall ME, Virtamo J, Haukka JK, Aro A, Albanes D & Huttunen JK (2000) Prospective study of diet, lifestyle, and intermittent claudication in male smokers. Am J Epidemiol 151, 892-901.
148. Tsai MY, Arnett DK, Eckfeldt JH, Williams RR & Ellison RC (2000) Plasma homocysteine and its association with carotid intimal-medial wall thickness and prevalent coronary heart disease: NHLBI Family Heart Study. Atherosclerosis 151, 519-524.
149. van den Berg M, Franken DG, Boers GH, Blom HJ, Jakobs C, Stehouwer CD & Rauwerda JA (1994) Combined vitamin B6 plus folic acid in young patients with atherosclerosis and hyperhomocysteinaemia. J Vasc Surg 20, 933-940.
150. van Tol A, van der Gaag MS, Scheek LM, van Gent T & Hendriks HF (1998) Changes in postprandial lipoproteins of low and high density caused by moderate alcohol consumption with dinner. Atherosclerosis 141, 101-103.
151. Verhoef P, Stampfer MJ, Buring JE, Gaziano JM, Allen RH, Stabler SP, Reynolds RD, Kok FJ, Hennekens CH & Willett WC (1996) Homocysteine metabolism and risk of myocardial infarction: relation with vitamins B6, B12, and folate. Am J Epidemiol 143, 845-859.
152. Vicaut E (1995) Opposite effects of red blood cell aggregation on resistance to blood flow. J Cardiovasc Surg 36, 361-368.
153. Violi F, Criqui M, Longoni A & Castiglioni C (1996) Relation between risk factors and cardiovascular complications in patients with peripheral arterial disease: results from the A.D.E.P. study. Atherosclerosis 120, 25-35.
154. Vogt MT, Wolfson SK & Kuller LH (1993) Segmental arterial disease in the lower extremities: correlates of disease and relationship to mortality. J Clin Epidemiol 46, 1267-1276.
155. Wald DS, Law M & Morris JK (2002) Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ 325, 1202-1206.
156. Wall RT, Harlan JM, Harker LA & Striker GE (1980) Homocysteine-induced endothelial cell injury in vitro: a model for the study of vascular injury. Thromb Res 18, 113-121.
157. Wang J, Dudman NP & Wilcken DE (1993) Effect of homocysteine and related compounds on prostacyclin production by cultured human vascular endothelial cells. Thromb Haemost 70, 1047-1052.
158. Weiss N, Keller C, Hoffmann U & Loscalzo J (2002) Endothelial dysfunction and atherothrombosis in mild hyperhomocysteinemia. Vasc Med 7, 227-239.
159. Welch GN & Loscalzo J (1998) Homocysteine and atherothrombosis. N Engl J Med 338, 1042-1050.
160. Westheim AS, Brox D & Selvaag OAW (1975) D-alpha-tokoferol ved claudication intermittens (D-alpha-Tocopherol in intermittent claudication; article in Norwegian). Tidsskr Norske Laegeforen 95, 13-15.
161. Williams HT, Fenna D & Macbeth RA (1971) Alpha tocopherol in the treatment of intermittent claudication. Surg Gynecol Obstet 132, 662-666.
162. Wilmink AB, Welch AA, Quick CR, Burns PJ, Hubbard CS, Bradbury AW & Day NE (2004) Dietary folate and vitamin B6 are independent predictors of peripheral arterial occlusive disease. J Vasc Surg 39, 513-516.
163. Woodcock BE, Smith E, Lambert WH, Jones WM, Galloway JH, Greaves M & Preston FE (1984) Beneficial effect of fish oil on blood viscosity in peripheral vascular disease. Br Med J (Clin Res Ed) 288, 592-594.
164. World Health Organization Study Group (2003) Diet, Nutrition and Prevention of Chronic Diseases. Report of the Joint WHO/FAO Expert Consultation. WHO Technical Report Series, no. 916. Geneva: WHO.
165. Yataco AR, Corretti MC, Gardner AW, Womack CJ & Katzel LI (1999) Endothelial reactivity and cardiac risk factors in older patients with peripheral arterial disease. Am J Cardiol 83, 754-758.